News

In a 31-center phase 2 trial in 10 countries, apecotrep BI 764198 reduced proteinuria in patients with primary focal segmental glomerulosclerosis.

Frikke-Schmidt discusses the newfound genetic correlation between vascular-related dementia and an increased BMI, partially mediated by high blood pressure.

In this Q&A, Mathioudaki discusses the post-hoc FLAME trial, which links ICS and LAMA discontinuation to transient exacerbation risk in COPD.

At the 2026 Maui Derm Hawaii meeting, recent data on icotrokinra’s use in patients with psoriasis were highlighted.

Neal Bhatia, MD, speaks in this interview regarding his discussion at Maui Derm Hawaii of new and emerging therapies in dermatology.

ASH’s new president, Robert Negrin, explains key takeaways from the 67th meeting and sets the scene for ASH 2026.

This interview from the Maui Derm 2026 conference features Lawrence Eichenfield, MD, discussing takeaways from his talk ‘Acne and Rosacea: Update 2026.’

As the January 31 PDUFA date approaches, Golden discusses that epinephrine sublingual film may deliver symptom relief as rapidly as autoinjectors, with added portability.

Andrew Kau, MD, PhD, and Audrey John, MD, PhD, discuss their recent research exploring exhaled breath analysis as a noninvasive way to probe the gut microbiome.

FDA prioritizes centanafadine's review for ADHD treatment, offering a novel first-in-class NDSRI option for adults, adolescents, and children.

This interview segment continues with Paul Nghiem, MD, PhD, highlighting notable insights from his session on cutaneous oncology.

Paul Nghiem highlights several key takeaways from his talk on cutaneous oncology, touching on various advances in skin cancer management.

Greater exposure to preparation therapy before psychedelic dosing was linked to larger reductions in depressive symptoms, a new study found.

Abou-Ghayda breaks down the association between ED and CVD and how this study introduces a new way to address this sensitive topic.

In a talk given at the Maui Derm 2026 conference, Neal Bhatia, MD, and Ted Rosen, MD, speak on new and upcoming therapies for dermatologic diseases for 2026.

A scoping review of 18 trials finds psychological, nutritional, and exercise support consistently benefits kidney cancer patients.

MannKind Therapeutics has announced new starting dose recommendations for patients with type 1 diabetes switching from injected or insulin pump mealtime therapy.

Lund highlights the value of preventive treatment in patients with prediabetes on the environment via reduced greenhouse gas emissions.

Proteomic fragmentation may explain reduced allergenicity and point to a safer substrate for peanut oral immunotherapy compared with current options, new data suggests.

Siegel addressed additional points presented in his Maui Derm 2026 session, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

In this interview, Siegel highlights key points presented in his Maui Derm 2026 talk, 'How To Maximize Your Billing Effectiveness in the Era of Dwindling Reimbursements and ICD-10.'

An audio recap of the top 5 stories in healthcare news from the week of 01/18-01/24.

This interview with Lim highlights knowledge gaps examined by an international expert panel reviewing existing literature on dermatologic disease in skin of color.

Stay updated with the latest healthcare breakthroughs, including new phase 2/3 data and updated asthma guidelines, in this week’s essential news roundup.

D’Amato explains his research on the biological mechanisms that control bowel movements and vitamin B1’s potential role in gut motility.

The first scoping review of kidney cancer pre/ rehabilitation suggests psychological support outdoes exercise and nutrition.

Fonseca explains the structure and goals of the ongoing trial, which has enrolled its first patient to clofutriben treatment against hard-to-control T2D.

New data show heat- and pressure-treated peanuts significantly reduce IgE binding, skin test reactivity, and oral challenge severity in allergic patients.